Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
35
ATOS Quote, Financials, Valuation and Earnings
Last price:
$0.76
Seasonality move
:
-36.83%
Day range:
$0.73 - $0.77
52-week range:
$0.55 - $1.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.97x
Volume:
708.2K
Avg. volume:
570.3K
1-year change:
-35.09%
Market cap:
$98.1M
Revenue:
--
EPS (TTM):
-$0.23
Analysts' Opinion
-
Consensus RatingAtossa Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.69, Atossa Therapeutics, Inc. has an estimated upside of 648.85% from its current price of $0.76.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing -426.66% downside risk from its current price of $0.76.
Fair Value
-
According to the consensus of 3 analysts, Atossa Therapeutics, Inc. has 648.85% upside to fair value with a price target of $5.69 per share.
ATOS vs. S&P 500
-
Over the past 5 trading days, Atossa Therapeutics, Inc. has underperformed the S&P 500 by -2.72% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Atossa Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Atossa Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Atossa Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Atossa Therapeutics, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Atossa Therapeutics, Inc. reported earnings per share of -$0.07.
Enterprise value:
46.2M
EV / Invested capital:
0.93x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.34x
EV / Free cash flow:
-1.76x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$16K
Return On Assets:
-43.21%
Net Income Margin (TTM):
--
Return On Equity:
-47.46%
Return On Invested Capital:
-47.46%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$11K | -$27K | -$16K | -$4K | -$4K | |
| Operating Income | -$30.5M | -$29.5M | -$32.9M | -$6.4M | -$9.3M | |
| EBITDA | -$30.5M | -$29.5M | -$32.8M | -$6.4M | -$9.2M | |
| Diluted EPS | -$0.24 | -$0.21 | -$0.23 | -$0.06 | -$0.07 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $143M | $123.4M | $97.6M | $77.1M | $55.7M | |
| Total Assets | $143M | $126.7M | $101.7M | $79.5M | $58M | |
| Current Liabilities | $1.7M | $2.9M | $3.4M | $5.8M | $8.2M | |
| Total Liabilities | $1.7M | $2.9M | $3.4M | $5.8M | $8.2M | |
| Total Equity | $141.3M | $123.9M | $98.3M | $73.7M | $49.8M | |
| Total Debt | $1.2K | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$19.9M | -$19.6M | -$26.3M | -$4.8M | -$6M | |
| Cash From Investing | -$2M | -$19K | -$16K | -$10K | -$7K | |
| Cash From Financing | -$1.5M | $304K | $3.4M | -- | -- | |
| Free Cash Flow | -$19.9M | -$19.6M | -$26.3M | -$4.8M | -$6M | |
ATOS
Sector
Market Cap
$98.1M
$28.4M
Price % of 52-Week High
58.5%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-3.01%
-1.32%
1-Year Price Total Return
-35.09%
-22.19%
Beta (5-Year)
0.950
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.75
200-day SMA
Sell
Level
$0.82
Bollinger Bands (100)
Sell
Level
0.76 - 0.94
Chaikin Money Flow
Sell
Level
-210.1M
20-day SMA
Sell
Level
$0.78
Relative Strength Index (RSI14)
Sell
Level
42.39
ADX Line
Sell
Level
17.6
Williams %R
Neutral
Level
-54.7821
50-day SMA
Sell
Level
$0.88
MACD (12, 26)
Sell
Level
-0.04
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
1B
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (10.7509)
Buy
CA Score
(Annual)
Level (0.1164)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (7.975)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
Stock Forecast FAQ
In the current month, ATOS has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ATOS average analyst price target in the past 3 months is $5.69.
-
Where Will Atossa Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Atossa Therapeutics, Inc. share price will rise to $5.69 per share over the next 12 months.
-
What Do Analysts Say About Atossa Therapeutics, Inc.?
Analysts are divided on their view about Atossa Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Atossa Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Atossa Therapeutics, Inc.'s Price Target?
The price target for Atossa Therapeutics, Inc. over the next 1-year time period is forecast to be $5.69 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ATOS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Atossa Therapeutics, Inc. is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ATOS?
You can purchase shares of Atossa Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Atossa Therapeutics, Inc. shares.
-
What Is The Atossa Therapeutics, Inc. Share Price Today?
Atossa Therapeutics, Inc. was last trading at $0.76 per share. This represents the most recent stock quote for Atossa Therapeutics, Inc.. Yesterday, Atossa Therapeutics, Inc. closed at $0.76 per share.
-
How To Buy Atossa Therapeutics, Inc. Stock Online?
In order to purchase Atossa Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ATOS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ATOS
Sector
P/E ratio
--
23.66x
PEG ratio
-0.34x
-0.01x
P/B ratio
1.97x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
ATOS
Sector
Revenue growth
--
4.85%
Earnings growth
-17.04%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.07
-$0.20
Profitability
ATOS
Sector
Profitability FY 2024
-$17K
$3.6M
Return on invested capital
-47.46%
-30.98%
Return on assets
-43.21%
-27.62%
Return on equity
-47.46%
-36.69%
Earnings Date
Last Earnings Date
Mar
17
Next Earnings Date
Dec
5
Estimated Next Earnings Date
Mar
6
Balance Sheet
ATOS
Sector
Total cash
$52M
$27.2M
Short term investments
--
$25.7M
Total assets
$76.4M
$79.9M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
38
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
